Breast cancer is a widespread disease that affects women globally. Diagnostic processes and remedial approaches to breast carcinogenesis have improved in recent decades, but continuous survival of patients with breast carcinogenesis is still lacking due to increased cell proliferation. The aim of the present work is to explore the anticell proliferative effects of nobiletin (NOB) against 7,12-dimethylbenz[a]anthracene (DMBA)-treated mammary tumorigenesis in rats. We stimulate mammary carcinogenesis using oral gavage of DMBA (25 mg/kg body weight) mixed with olive oil (1 mL). This results in reduced body weight; increased liver marker enzymes such as alkaline phosphatase, acid phosphatase, aspartate aminotransferase, and alanine aminotransferase; and cell proliferative markers such as c-Jun, proliferating cell nuclear antigen, c-Fos, cyclin D1, and activating protein-1 (AP-1) in the DMBA-treated cancer-bearing animals. NOB administration improved body weight, significantly reduced hepatic marker enzymes, and altered histopathological changes. Furthermore, NOB efficiently reduced tumor cell proliferation markers in DMBA-induced mammary carcinogenesis. Overall, these results suggest that NOB has an anticell proliferative effect on DMBA-induced mammary cancer via modulation of the AP-1 signaling pathway.

中文翻译：

---

Nobiletin通过调节7，12-二甲基苯并[a]蒽诱导的乳腺癌致癌作用中的激活蛋白1信号通路来减轻细胞增殖。

乳腺癌是一种广泛影响全球女性的疾病。在最近的几十年中，乳腺癌的诊断过程和治疗方法得到了改善，但是由于细胞增殖的增加，仍然缺乏乳腺癌患者的持续生存。本工作的目的是探讨诺比列汀（NOB）对大鼠7,12-二甲基苯并[a]蒽（DMBA）治疗的乳腺肿瘤发生的抗细胞增殖作用。我们通过将DMBA（25 mg / kg体重）与橄榄油（1 mL）混合口服灌胃来刺激乳腺癌的发生。这导致体重减轻；增加肝脏标志物酶，例如碱性磷酸酶，酸性磷酸酶，天冬氨酸转氨酶和丙氨酸转氨酶；和细胞增殖标记，例如c-Jun，增殖细胞核抗原，c-Fos，细胞周期蛋白D1，和经DMBA治疗的荷瘤动物中活化蛋白1（AP-1）的活化。NOB给药可改善体重，显着减少肝标志物酶，并改变组织病理学变化。此外，NOB有效降低了DMBA诱导的乳腺癌致癌作用中的肿瘤细胞增殖标志物。总体而言，这些结果表明，NOB通过调节AP-1信号传导途径对DMBA诱导的乳腺癌具有抗细胞增殖作用。